In the intestines of cattle lives a microscopic warrior: a peptide so effective at breaking down bacterial defenses that it may soon transform how we treat some of medicine's most stubborn infections. Researchers at UCF College of Medicine have spent four years unraveling exactly how this naturally occurring antimicrobial peptide, called Bac7, disarms drug-resistant Klebsiella pneumoniae bacteria — a discovery that could reshape treatment for infections that currently resist nearly every antibiotic on the shelf.
The stakes are staggeringly high. About 80% of bacterial infections being treated in clinics involve bacteria living in protective biofilm communities — slimy, gooey coatings that act like an impenetrable fortress, allowing germs to survive antibiotics that would otherwise kill them. Klebsiella pneumoniae, a bacterium normally harmless in the human gut, becomes dangerous when it spreads through the bloodstream to the liver, kidneys, and spleen, especially in immunocompromised patients or those exposed to contaminated medical devices. The resulting infections — pneumonia, wound infections, urinary tract infections — are notoriously difficult to treat.
Assistant Professor Renee Fleeman and her team have discovered something remarkable: the Bac7 peptide works through a dual attack that essentially tricks bacteria into abandoning their protective shields. The peptide simultaneously damages the bacterial membrane and disrupts protein synthesis, triggering what Fleeman describes as "a double punch." This two-pronged assault causes a genetic cascade within the bacterium that makes it sense danger and break free from its own biofilm — the very defense mechanism that normally keeps it safe from antibiotics and immune system attack.
"By hitting the membrane as well as protein synthesis at the same time, it's a double punch that triggers a genetic change in the cell to make it think it needs to break out of the biofilm as a response to our peptide," Fleeman explained. Once the bacteria abandon their biofilm refuge, they become vulnerable. Suddenly, standard antibiotics that previously bounced off the protective coating can penetrate and destroy the exposed germs. The body's own immune system gains the upper hand too.
The research, recently published in PLOS Pathogens, demonstrates that Bac7 can weaken and kill biofilm-embedded bacteria in animal models — a critical validation as the team moves toward human applications. Fleeman's lab has also shown that the peptide can decrease bacterial load at the infection source while simultaneously limiting the bacteria's ability to spread through the bloodstream, essentially fighting the infection on two fronts.
The vision ahead is practical and grounded. The team envisions eventually developing a topical cream containing the Bac7 peptide that could weaken bacterial biofilm defenses on wounds or infected tissue, allowing standard antibiotics to work far more effectively than they currently can. Rather than replacing existing antibiotics entirely, the peptide would work synergistically with them — a partnership that could resurrect the power of drugs that bacteria have grown resistant to over years of antibiotic exposure.
"We're moving our research forward and we're very hopeful," Fleeman said. For patients living with chronic, antibiotic-resistant infections, that hope carries real weight. A naturally derived peptide from cattle might soon become the key that unlocks a fortress bacteria have held for too long.